Ventyx Biosciences VTYX 深 滬
已收盤 03-04 16:00:00 美东时间
14.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 14.00
- 總市值 10.05亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.783
- 委 比 0.00%
- 總股本 7176.08万
- 歷史最高 47.2508
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.783
- 每 手 1
- 風險率 4.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eli Lilly Expands Into Sleep Medicine With Centessa Buyout
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
03-31 22:48
UPDATE 2-Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet
UPDATE 2-Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet Adds details throughout March 31 (Reuters) - Eli Lilly LLY.N said on Tuesday it would buy Centessa Pharmaceuticals 260y.F in a deal valued at up to $7.8 billion as the U.S. drugmaker looks to diversify beyond its metabol
03-31 19:08
Ventyx Biosciences Completes Cash Merger and Equity Payout
Ventyx Biosciences ( ($VTYX) ) has shared an update. On the closing date of a p...
03-04 22:49
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Oppenheimer Downgrades Ventyx Biosciences to Perform
Oppenheimer analyst Jeff Jones downgrades Ventyx Biosciences (NASDAQ:VTYX) from Outperform to Perform.
01-09 02:05
Alphabet To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-08 21:13
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
Lilly To Acquire Ventyx Biosciences For $14.00/Share In All-Cash Deal Valued At ~$1.2B
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammationAcquisition builds on Lilly's established capabilities in inflammatory-mediated
01-08 05:19
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in infla...
01-08 05:17
